Categories:Radiotherapy

First Order of C-RAD Catalyst from UK Customer

C-RAD received an order for the James Cook University Hospital in Middlesbrough, UK. The customer decided for a Catalyst™ System including the software packages for Patient Positioning and Motion Monitoring.

The James Cook University Hospital in Middlesbrough will focus the use of the Catalyst System on the treatment of breast cancer patients. The installation is scheduled for the fourth quarter of the fiscal year 2014. C-RAD products are distributed by the company Vertec Scientific Ltd. in the UK.

The Catalyst system is based on a new generation hardware and software platform for high performance optical surface scanning and augmented reality through re-projection. Advanced and highly optimized algorithms for non-rigid registration and deformable models enable real-time assessment of patient positioning errors before and during treatment delivery. The system calculates isocenter adjustments and interfaces to major vendors ensure a completely integrated workflow.

Tim Thurn, CEO, C-RAD AB:

“With the James Cook University Hospital we have a cutting-edge radiation therapy center as our first reference in the UK. The first system in a country is always an important milestone to further develop the local market.”

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 28 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian  and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier. Erik Penser Bankaktiebolag is appointed as C-RAD’s Certified Adviser.

For more information on C-RAD, please visit www.c-rad.com.

For further information:

Tim Thurn, CEO C-RAD AB, Phone 46-18-666947, E-mail investors@c-rad.com